Arcutis director sells 10,000 shares under 10b5-1 plan

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock in an open-market transaction.

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares of common stock in an open-market transaction. The sale took place on March 2, 2026 at a weighted average price of $25.6518 per share, in multiple trades between $25.37 and $26.10. After this sale, he directly owned 49,744 shares. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025 with an end date of May 29, 2026.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Welgus Howard G.

Role Director

Sold 10,000 shs ($257K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$25.6518	$257K

Holdings After Transaction: Common Stock — 49,744 shares (Direct)

Footnotes (2)

1. F1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
2. F2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arcutis Biotherapeutics (ARQT) report for Howard G. Welgus?

Arcutis Biotherapeutics reported that director Howard G. Welgus sold 10,000 shares of common stock. The open-market transaction occurred on March 2, 2026 at a weighted average price of $25.6518 per share, executed in multiple trades within a disclosed price range.

At what prices did Howard G. Welgus sell Arcutis Biotherapeutics (ARQT) shares?

Howard G. Welgus sold the 10,000 shares at a weighted average price of $25.6518 per share. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, as disclosed in the Form 4 footnote.

How many Arcutis Biotherapeutics (ARQT) shares does Howard G. Welgus own after the reported sale?

Following the reported transaction, Howard G. Welgus directly owns 49,744 shares of Arcutis Biotherapeutics common stock. This figure reflects his holdings immediately after the 10,000-share open-market sale on March 2, 2026, as detailed in the Form 4 filing.

Was the Arcutis Biotherapeutics (ARQT) insider sale made under a 10b5-1 trading plan?

Yes, the sale was executed under a pre-arranged Rule 10b5-1 trading plan. The filing states the plan was adopted on March 11, 2025 by Howard G. Welgus and has a plan end date of May 29, 2026, governing the reported transaction.

What does the weighted average price mean in the Arcutis Biotherapeutics (ARQT) insider sale?

The weighted average price of $25.6518 represents the average sale price across multiple trades. Shares were sold at individual prices between $25.37 and $26.10. The insider undertook to provide detailed breakdowns of share counts at each price upon request.

What type of transaction did Howard G. Welgus execute in Arcutis Biotherapeutics (ARQT) stock?

Howard G. Welgus executed an open-market sale of Arcutis Biotherapeutics common stock. The Form 4 classifies the transaction as a non-derivative sale with code “S”, indicating a sale in the open market or a private transaction on March 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:16 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Welgus Howard G.

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		10,000	D	$25.6518(2)	49,744	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

	/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.